GRPZ - ETF AI Analysis
Top Page
Invesco S&P SmallCap 600 GARP ETF (GRPZ)
GRPZ, the Invesco S&P SmallCap 600 GARP ETF, has a solid overall rating driven mainly by strong, growth-focused holdings like Palomar Holdings, Dave, Sezzle, ADMA Biologics, and Tidewater, which show robust financial performance, positive earnings calls, and generally supportive technical trends. The rating is held back somewhat by names like TG Therapeutics and Inspire Medical Systems, where bearish technical signals, cash flow risks, and high valuation concerns introduce more uncertainty. The main risk factor is the ETF’s reliance on smaller, growth-oriented companies, which can be more volatile and sensitive to market swings and valuation pressures.
GRPZ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.19M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.91
- Issuer
- Invesco
- Inception Date
- Mar 27, 2024
- Dividend Yield
- 0.84%
- Asset Class
- Equity
- Index Tracked
- S&P SmallCap 600 GARP Index
GRPZ Summary
GRPZ is the Invesco S&P SmallCap 600 GARP ETF, which follows the S&P SmallCap 600 GARP Index. It focuses on smaller U.S. companies that are growing but still reasonably priced, giving investors a way to tap into the potential of small, expanding businesses. The fund is spread across many sectors, including financials, health care, and technology, and holds companies like Inspire Medical Systems and Paycom. Someone might invest in GRPZ for growth and diversification beyond large, well-known stocks. A key risk is that small-cap stocks can be more volatile, so the ETF’s value can move up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 invested. That cost is a bit higher than many broad, passively managed index ETFs because this fund uses a more specialized “growth at a reasonable price” strategy in the small-cap space.
What would affect this ETF?
GRPZ could benefit if the U.S. economy grows steadily, as small-cap companies in sectors like financials, health care, and technology often see stronger business results, and successful innovation at top holdings such as Inspire Medical Systems or Paycom could further support performance. On the downside, higher interest rates, an economic slowdown in the U.S., or tighter regulations on financial and health care firms could hurt smaller companies more than large ones and increase volatility for this ETF.
GRPZ Top 10 Holdings
GRPZ is leaning hard into U.S. small-cap growth, with health care and tech names doing much of the heavy lifting. TG Therapeutics, Paycom, and Sezzle have been rising sharply this year, giving the fund a strong growth engine, while Tidewater adds a steady boost from the energy side. On the flip side, Inspire Medical Systems and ADMA Biologics are lagging year-to-date, acting like a bit of sand in the gears despite recent short-term strength. Overall, the ETF is a U.S.-focused, small-cap growth story with a clear tilt toward innovative health care and tech.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 INSP | Inspire Medical Systems | 2.45% | $77.43K | $1.97B | -6.80% | 73Outperform |
 ADMA | ADMA Biologics | 2.15% | $67.91K | $2.56B | -25.28% | 78Outperform |
 TGTX | TG Therapeutics | 2.09% | $66.01K | $9.36B | 79.84% | 65Neutral |
 PLMR | Palomar Holdings | 1.96% | $62.02K | $3.69B | 24.73% | 83Outperform |
 DAVE | Dave | 1.81% | $57.02K | $4.04B | 41.31% | 80Outperform |
 MRP | Millrose Properties Inc Class A | 1.87% | $59.08K | $3.95B | -20.88% | ―― |
 PAYC | Paycom | 1.92% | $60.77K | $11.70B | 42.59% | 76Outperform |
 SEZL | Sezzle Inc. | 1.85% | $58.26K | $4.56B | 107.21% | 80Outperform |
 TDW | Tidewater | 1.79% | $56.42K | $4.35B | 73.14% | 78Outperform |
 QNST | Quinstreet | 1.74% | $55.09K | $995.69M | 19.26% | 69Neutral |
GRPZ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GRPZ, the sentiment is Positive. The current price of 31.54 is above the 20-day moving average (MA) of 31.14, below the 50-day MA of 31.58, and above the 200-day MA of 30.22, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 53.96 is Neutral, neither overbought nor oversold. The STOCH value of 66.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRPZ.
GRPZ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GRPZ | $31.54 | $35.00(10.97% Upside) | $3.19M | 0.35% | 73Outperform |
 RUSC | $36.75 | $50.00(36.04% Upside) | $85.25M | 0.64% | 64Neutral |
 AIMS | $26.93 | $34.54(28.30% Upside) | $84.74M | 0.75% | 65Neutral |
 BKSE | $42.73 | $52.82(23.60% Upside) | $83.90M | 0.04% | 65Neutral |
 STXK | $36.85 | $46.08(25.04% Upside) | $79.32M | 0.18% | 65Neutral |
 SYZ | $29.36 | $36.87(25.58% Upside) | $63.23M | 0.61% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GRPZ | Invesco S&P SmallCap 600 GARP ETF | 31.54 | 5.71 | 22.09% | |
| RUSC | US Small Cap Equity Active ETF | 36.75 | 6.32 | 20.75% | |
| AIMS | Acuitas Small Cap Active ETF | 26.93 | 1.75 | 6.93% | |
| BKSE | BNY Mellon US Small Cap Core Equity ETF | 42.73 | 6.40 | 17.61% | |
| STXK | Strive 2000 ETF | 36.85 | 4.25 | 13.05% | |
| SYZ | Lazard US Systematic Small Cap Equity ETF | 29.36 | 5.08 | 20.93% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.